ALGN vs NVST vs XRAY Stock Comparison

Align Technology, Envista Holdings and Dentsply Sirona Prices as of Nov 13, 2026 Peers: Industry group
ALGN Align Technology Inc
$168.32 +16.5% 1M +20.7% 1Y
Market cap
$11.78B
P/E
24.0x
Revenue (TTM)
$4.16B
Div. yield
–
Dental Healthcare
2 wins

Head to Head

11 decided of 12

Envista Holdings leads on 8 of the 12 questions below (Envista Holdings 8, Align Technology 2, Dentsply Sirona 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionALGNNVSTXRAYLeader
Larger companyMarket capitalisation $11.78B $3.86B $1.77B ALGN
Cheaper on earningsLower P/E, profitable companies only 24.0x 6.1x -14.7x NVST
Cheaper on forward earningsLower price / next fiscal year consensus EPS 15.5x 16.0x 6.8x XRAY
Faster revenue growthRevenue growth, trailing twelve months +4.4% +9.8% -1.4% NVST
More profitableNet margin, trailing twelve months 11.8% 22.0% -3.4% NVST
Better return on capitalReturn on invested capital — 15.0% -1.5% NVST
Less leveragedLower net debt / EBITDA — 0.3x 7.1x NVST
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +20.7% +23.2% -16.3% NVST
Better 5-year returnAnnualised price return, 5 years -24.6%/yr -10.8%/yr -30.1%/yr NVST
Less volatileAnnualised volatility, 1 year 40.3% 40.7% 48.1% ALGN
Higher overall scoreMean of the five percentile scores vs peers 70/100 81/100 63/100 NVST

Percentile Scorecard

ALGNNVSTXRAY

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisALGNNVSTXRAY
Valuation 85 #37 of 243 98 #7 of 243 93 #17 of 243
Growth 38 #142 of 228 74 #60 of 228 51 #112 of 228
Profitability 87 #29 of 222 86 #31 of 222 67 #73 of 222
Financial Health 48 #130 of 248 50 #125 of 248 15 #211 of 248
Shareholder Returns 92 #13 of 158 98 #5 of 158 86 #23 of 158
Overall 70 81 63
  • ALGN ranked among 252 companies in Medical Devices and Diagnostics
  • NVST ranked among 252 companies in Medical Devices and Diagnostics
  • XRAY ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodALGNNVSTXRAYSPY
1 month +16.5%+7.3%+8.5% -2.0%
3 months -7.2%-12.7%-21.0% -2.8%
6 months +7.0%+5.5%-9.0% +2.0%
Year to date +7.8%+12.9%-19.9% +10.6%
1 year +20.7%+23.2%-16.3% +12.2%
3 years -17.0%+9.6%-68.3% +68.1%
3 years, per year -6.0%+3.1%-31.9% +18.9%
5 years -75.5%-43.4%-83.3% +61.4%
5 years, per year -24.6%-10.8%-30.1% +10.1%
10 years +83.9%—-84.8% +248.5%
10 years, per year +6.3%—-17.2% +13.3%

Risk

MeasureALGNNVSTXRAYSPY
Volatility, 1Y 40.3%40.7%48.1% 13.6%
Downside volatility, 1Y 37.6%37.3%45.6% 13.9%
Beta vs S&P 500, 1Y 1.331.311.17 1.00
Return / volatility, 1Y 0.510.57-0.34 0.90
Max drawdown, 5Y -82.0%-71.0%-85.7% -25.4%
From 52-week high -14.8%-19.0%-37.6% -3.2%
52-week high $197.51$30.26$14.68 $779.14
52-week low $132.28$18.95$8.42 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleALGNNVSTXRAY
P/E now vs peer median 24.3xmedian 26.5x 6.2xmedian 26.5x -15.1xmedian 26.5x
P/S now vs peer median 2.9xmedian 2.7x 1.4xmedian 2.7x 0.5xmedian 2.7x
EV/EBITDA now vs peer median 12.5xmedian 18.4x 5.0xmedian 18.4x 13.5xmedian 18.4x
P/FCF now vs peer median 19.7xmedian 25.4x 16.2xmedian 25.4x 17.6xmedian 25.4x
P/B now vs peer median 2.8xmedian 2.5x 1.3xmedian 2.5x 1.3xmedian 2.5x
PEG now vs peer median 1.78median 0.98 0.12median 0.98 -0.97median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsALGNNVSTXRAY
Revenue $4.16B $2.88B $3.58B
Gross profit $2.88B $1.61B $1.81B
Operating income $620.46M $731.30M -$55.00M
Net income $491.87M $633.60M -$122.00M
Free cash flow $602.50M $242.00M $103.00M
R&D $377.60M $121.80M $171.00M
EPS (diluted) $6.93 $3.88 $-0.61
Cash & equivalents $1.14B $1.16B $195.00M
Total debt – $1.43B $2.20B
Shares (diluted) 71.02M 163.40M 199.20M
Enterprise value $7.55B -$717.29M $822.66M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricALGNNVSTXRAY
P/E 24.3x 6.2x -15.1x
P/FCF 19.7x 16.2x 17.6x
P/Operating cash flow 15.9x 13.0x 6.7x
P/S 2.9x 1.4x 0.5x
P/B 2.8x 1.3x 1.3x
P/Tangible book 2.8x 1.6x 3.4x
EV/EBITDA 12.5x 5.0x 13.5x
EV/EBIT 17.3x 5.7x -69.5x
EV/Revenue 2.6x 1.5x 1.1x
EV/FCF 17.8x 17.3x 37.1x
EV/Operating cash flow 14.3x 13.9x 14.0x
PEG (3Y EPS CAGR) 1.78 0.12 -0.97

Growth

14 metrics
MetricALGNNVSTXRAY
Revenue growth (1Y) 4.4% 9.8% -1.4%
Revenue CAGR (3Y) 3.0% 3.7% -3.2%
Gross profit growth (1Y) 5.5% 11.0% -2.0%
Gross profit CAGR (3Y) 2.7% 3.0% -4.6%
Operating income growth (1Y) 16.1% 287.1% 93.1%
Operating income CAGR (3Y) 2.0% 31.4% 16.1%
Net income growth (1Y) 30.0% 4,041% 86.2%
Net income CAGR (3Y) 10.7% 49.2% 17.7%
EPS growth (1Y) 32.6% 4,110% 86.3%
EPS CAGR (3Y) 13.6% 52.7% 15.6%
Operating cash flow growth (1Y) 14.3% 0.6% 23.1%
Operating cash flow CAGR (3Y) -5.3% 2.0% -8.8%
Free cash flow growth (1Y) 6.3% -7.8% 28.8%
Free cash flow CAGR (3Y) -4.2% 3.7% -22.1%

Profitability

14 metrics
MetricALGNNVSTXRAY
Gross margin 69.1% 55.9% 50.5%
EBITDA margin 20.6% 29.3% 7.9%
Operating margin 14.9% 25.4% -1.5%
Pretax margin 15.5% 23.8% -2.5%
Net margin 11.8% 22.0% -3.4%
FCF margin 14.5% 8.4% 2.9%
Operating cash flow margin 18.0% 10.5% 7.6%
Return on equity 11.5% 20.6% -9.0%
Return on assets 7.6% 11.3% -2.3%
Return on invested capital – 15.0% -1.5%
Return on capital employed 13.6% 15.3% -1.4%
Asset turnover 0.6x 0.5x 0.7x
Cash conversion (OCF / net income) 1.5x 0.5x -2.2x
Stock comp / revenue 4.1% 1.4% 0.9%

Financial Health

11 metrics
MetricALGNNVSTXRAY
Debt / assets – 25.5% 42.4%
Debt / equity – 0.5x 1.6x
Net debt / EBITDA – 0.3x 7.1x
Debt / FCF – 5.9x 21.4x
Liabilities / assets 34.0% 45.0% 73.9%
Equity / assets 66.0% 55.0% 26.1%
Interest coverage – – -0.6x
Current ratio 1.4x 2.5x 1.6x
Quick ratio 1.2x 2.0x 0.7x
Cash ratio 0.6x 1.4x 0.2x
Altman Z-score 4.89 2.17 0.70

Shareholder Returns

7 metrics
MetricALGNNVSTXRAY
Dividend yield – – 1.7%
Net buyback yield 2.3% 3.4% 0.7%
Shareholder yield 2.3% 3.4% 2.5%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusALGNNVSTXRAY
Forward P/E 15.5xFY2026 16.0xFY2026 6.8xFY2026
EPS, next fiscal year $10.86FY2026 $1.53FY2026 $1.35FY2026
EPS growth, next FY +3.3%FY2026 +28.6%FY2026 -15.6%FY2026
EPS growth, the year after +16.6% +15.0% -1.5%
Revenue, next fiscal year $3.84BFY2026 $2.98BFY2026 $3.63BFY2026
Revenue growth, next FY -4.7%FY2026 +9.4%FY2026 -1.4%FY2026
Revenue growth, the year after +3.1% +2.6% +1.0%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersALGNNVSTXRAY
Held by institutions 100.0% 100.0% 100.0%
Institutions holding 678 382 378
Change in shares held, QoQ +4.2% +6.4% +6.1%
Institutions buying 293 200 207
Institutions selling 268 129 116
Buyers to sellers 1.09 1.55 1.78

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ALGNNVSTXRAY
ALGN 1.00 0.71 0.60
NVST 0.71 1.00 0.63
XRAY 0.60 0.63 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ALGN, NVST and XRAY?

Align Technology (ALGN) is the largest by market capitalisation: Align Technology (ALGN) $11.78B, Envista Holdings (NVST) $3.86B, Dentsply Sirona (XRAY) $1.77B.

Which stock is cheaper, ALGN, NVST and XRAY?

Envista Holdings (NVST) trades on the lowest price-to-earnings ratio (Align Technology (ALGN) 24.0x, Envista Holdings (NVST) 6.1x, Dentsply Sirona (XRAY) -14.7x). On next year's consensus earnings, Dentsply Sirona (XRAY) is cheapest (Align Technology (ALGN) 15.5x, Envista Holdings (NVST) 16.0x, Dentsply Sirona (XRAY) 6.8x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Envista Holdings (NVST) grew revenue fastest over the trailing twelve months: Align Technology (ALGN) +4.4%, Envista Holdings (NVST) +9.8%, Dentsply Sirona (XRAY) -1.4%.

Which company is more profitable?

Envista Holdings (NVST) has the highest net margin (Align Technology (ALGN) 11.8%, Envista Holdings (NVST) 22.0%, Dentsply Sirona (XRAY) -3.4%). On return on invested capital, Envista Holdings (NVST) leads (Envista Holdings (NVST) 15.0%, Dentsply Sirona (XRAY) -1.5%).

Which stock has performed better?

Over the past year Envista Holdings (NVST) returned the most: Align Technology (ALGN) +20.7%, Envista Holdings (NVST) +23.2%, Dentsply Sirona (XRAY) -16.3%. Over five years, Envista Holdings (NVST) compounded fastest (Align Technology (ALGN) -24.6%/yr, Envista Holdings (NVST) -10.8%/yr, Dentsply Sirona (XRAY) -30.1%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Align Technology (ALGN) has been the steadiest (Align Technology (ALGN) 40.3%, Envista Holdings (NVST) 40.7%, Dentsply Sirona (XRAY) 48.1%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ALGN, NVST and XRAY?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Envista Holdings (NVST) leads on 8. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.